Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

Episode 398

0:00-28:50

J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III. The analysts also assess how a growing neoantigen vaccine pipeline is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed. View full story: https://www.biocentury.com/article/661638 #NewCos #BiotechMA #CancerVaccines #FDA #Ophthalmology 0:01 Sponsor Message: Tigermed 1:58 J&J’s Ollin Acquisition 5:18 Blackstone’s Risk Sharing 9:13 Neoantigen Vaccine Pipeline 17:29 Overton’s FDA Nomination 24:40 Acting Commissioner Scenarios To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Publisher

BioCentury This Week

Published

November 17, 2026

Duration

29 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BioCentury

BT

BioCentury This Week

@biocenturythisweek

#neoantigenvaccines #overtonodds #lifesciences

The Nile